Skip to main content

Table 1 Disease characteristics of patients in non-LCT group and LCT group

From: The value of local consolidative therapy in Osimertinib-treated non-small cell lung cancer with oligo-residual disease

  no-LCT (94) LCT (14) p value
Sex 0.63
 female 54(57.4%) 9(64.3%)  
 male 40(42.6%) 5(35.7%)  
Age (years) 0.36
 Median (range) 62(38–83) 61(35–70)  
Smoking 0.29
 no 53(56.4%) 10(71.4%)  
 yes 41(43.6%) 4(28.6%)  
T stage 0.30
 T0–2 78(83.0%) 13(92.9%)  
 T3–4 16(17.0%) 2(7.1%)  
N stage 0.36
 N0 48(51.1%) 9(64.3%)  
 N1–3 46(48.9%) 5(35.7%)  
EGFR mutation 0.49
 19del 45(47.9%) 7(50.0%)  
 L858R 44(46.8%) 7(50.0%)  
 others 5(5.3%) 0(0.0%)  
No. mets 0.018
  ≤ 2 42(44.7%) 11(78.6%)  
  > 2 52(55.3%) 3(21.4%)  
No. mets. Organs 0.13
  ≤ 2 86(91.5%) 14(100%)  
  > 2 8(8.5%) 0(0.0%)  
Lung mets 0.006
 no 31(33.0%) 10(38.0%)  
 yes 63(67.0%) 4(28.6%)  
Bone mets 0.51
 no 66(70.2%) 11(78.6%)  
 yes 28(29.8%) 3(21.4%)  
Adrenal gland mets 1.00
 no 89(94.7%) 14(100%)  
 yes 5(5.3%) 0(0.0%)  
Brain mets 0.07
 no 64(68.1%) 6(42.9%)  
 yes 30(31.9%) 8(57.1%)  
LN mets 0.29
 no 53(56.4%) 10(71.4%)  
 yes 41(43.6%) 4(28.6%)  
Osimertinib 0.003
 First-line 17(18.1%) 8(57.1%)  
 Second-line 77(81.9%) 6(42.9%)  
  1. Abbreviations: LCT local consolidative therapy, No number, mets metastasis, LN lymph node